| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Microbiology and Immunology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541, USA
2 Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA
3 Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541, USA
Correspondence
Matthias J. Schnell
matthias.schnell{at}jefferson.edu
Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.
This article has been cited by other articles:
|
|
 |
|
  L. Du, G. Zhao, Y. Lin, H. Sui, C. Chan, S. Ma, Y. He, S. Jiang, C. Wu, K.-Y. Yuen, et al. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection J. Immunol., January 15, 2008; 180(2): 948 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. C. Cheng, S. K. P. Lau, P. C. Y. Woo, and K. Y. Yuen Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection Clin. Microbiol. Rev., October 1, 2007; 20(4): 660 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bukreyev, M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins Nonsegmented negative-strand viruses as vaccine vectors. J. Virol., November 1, 2006; 80(21): 10293 - 10306. [Full Text] [PDF]
|
|
|
|
|
|
L. Gillim-Ross and K. Subbarao Emerging Respiratory Viruses: Challenges and Vaccine Strategies Clin. Microbiol. Rev., October 1, 2006; 19(4): 614 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lavillette, R. Barbouche, Y. Yao, B. Boson, F.-L. Cosset, I. M. Jones, and E. Fenouillet Significant Redox Insensitivity of the Functions of the SARS-CoV Spike Glycoprotein: COMPARISON WITH HIV ENVELOPE J. Biol. Chem., April 7, 2006; 281(14): 9200 - 9204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Weiss and S. Navas-Martin Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus Microbiol. Mol. Biol. Rev., December 1, 2005; 69(4): 635 - 664. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
